145 related articles for article (PubMed ID: 7771503)
1. Case report: diabetic ketoacidosis in a patient with glucagonoma.
Anthony LB; Sharp SC; May ME
Am J Med Sci; 1995 Jun; 309(6):326-7. PubMed ID: 7771503
[TBL] [Abstract][Full Text] [Related]
2. Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update.
Fenkci SM; Fidan Yaylali G; Sermez Y; Akdam H; Sabir N; Kiraç S
Endocr Relat Cancer; 2005 Jun; 12(2):449-54. PubMed ID: 15947115
[TBL] [Abstract][Full Text] [Related]
3. [Glucagonoma with diabetic ketoacidosis; case report].
Lefebvre J; Lelièvre G; Dalle-Furnari MA; Proye C; Mazzuca M; Garraud JC; Luyckx A; Linquette M
Diabete Metab; 1982 Sep; 8(3):191-5. PubMed ID: 6292011
[TBL] [Abstract][Full Text] [Related]
4. [Malignant glucagonoma: an uncommon cause of new onset diabetes].
Guerrero Vázquez R; Oliva Rodríguez R; Cuenca Cuenca JI; Sánchez Alberdi F; Navarro González E
Endocrinol Nutr; 2011 Apr; 58(4):199-201. PubMed ID: 21334267
[No Abstract] [Full Text] [Related]
5. Reversal of a neurologic paraneoplastic syndrome with octreotide (Sandostatin) in a patient with glucagonoma.
Holmes A; Kilpatrick C; Proietto J; Green MD
Am J Med; 1991 Oct; 91(4):434-6. PubMed ID: 1951389
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses.
Moattari AR; Cho K; Vinik AI
Surgery; 1990 Sep; 108(3):581-7. PubMed ID: 2168587
[TBL] [Abstract][Full Text] [Related]
7. [Glucagonoma syndrome in a multihormonal pancreatic tumor].
Keller U; Fankhauser S; Schumacher A; Trimble ER; Heitz PU
Schweiz Med Wochenschr; 1982 Feb; 112(9):297-304. PubMed ID: 6281878
[TBL] [Abstract][Full Text] [Related]
8. [Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].
Bouin M; Aoust LD
Gastroenterol Clin Biol; 2002 Oct; 26(10):926-9. PubMed ID: 12434103
[TBL] [Abstract][Full Text] [Related]
9. A particularly aggressive combined glucagonoma and gastrinoma syndrome.
Balian A; Fromont C; Naveau S; Bonte E; Belloula D; Giraud V; Montembault S; Capron F; Chaput JC
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1417-9. PubMed ID: 10654804
[TBL] [Abstract][Full Text] [Related]
10. Glucagonoma syndrome with increased lactate dehydrogenase isoenzymes: octreotide treatment.
Siller GM; Strutton GM; Moore GA; Kanowski DM; Nedwich JA
Australas J Dermatol; 1994; 35(1):11-4. PubMed ID: 7528001
[TBL] [Abstract][Full Text] [Related]
11. Glucagonoma syndrome: diagnosis and treatment.
Zeng J; Wang B; Ma D; Li F
J Am Acad Dermatol; 2003 Feb; 48(2):297-8. PubMed ID: 12582409
[No Abstract] [Full Text] [Related]
12. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.
Rosenbaum A; Flourie B; Chagnon S; Blery M; Modigliani R
Digestion; 1989; 42(2):116-20. PubMed ID: 2548911
[TBL] [Abstract][Full Text] [Related]
13. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.
Jockenhövel F; Lederbogen S; Olbricht T; Schmidt-Gayk H; Krenning EP; Lamberts SW; Reinwein D
Clin Investig; 1994 Jan; 72(2):127-33. PubMed ID: 8186658
[TBL] [Abstract][Full Text] [Related]
14. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.
Kimbara S; Fujiwara Y; Toyoda M; Chayahara N; Imamura Y; Kiyota N; Mukohara T; Fukunaga A; Oka M; Nishigori C; Minami H
Clin J Gastroenterol; 2014 Jun; 7(3):255-9. PubMed ID: 26183746
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-secreting pancreatic islet cell carcinoma, containing insulin and somatostatin, with hypoglycemic attack.
Yano T; Yamamoto N; Fujimori K; Inamori S; Hayashi H; Mizumoto R
Am J Gastroenterol; 1982 Jun; 77(6):387-91. PubMed ID: 6124121
[TBL] [Abstract][Full Text] [Related]
16. Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections.
Lo CH; Ho CL; Shih YL
QJM; 2014 Feb; 107(2):157-8. PubMed ID: 23389434
[No Abstract] [Full Text] [Related]
17. Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema?
Manes G; Pellegrini A; Riccardi F; Uomo G
Ital J Gastroenterol; 1995 Jun; 27(5):248-9. PubMed ID: 8541575
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration.
Santangelo WC; Unger RH; Orci L; Dueno MI; Popma JJ; Krejs GJ
Pancreas; 1986; 1(5):464-9. PubMed ID: 2882503
[TBL] [Abstract][Full Text] [Related]
19. Effect of somatostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma-syndrome.
Schmid R; Allescher HD; Schepp W; Hölscher A; Siewert R; Schusdziarra V; Classen M
Hepatogastroenterology; 1988 Feb; 35(1):34-7. PubMed ID: 2896149
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogue and tissue cultures in the study of a human malignant glucagonoma.
Ahlman H; Ahlund L; Dahlström A; Grimelius L; Theodorsson E
J Surg Oncol; 1990 Jul; 44(3):191-9. PubMed ID: 2164620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
